Research areas
The role of PTTG1 securin in the development and progression of different neoplasias, as well as its possible application as a tumour marker.
Protein PTTG1 is homologous to Xenopus securin and is expressed abundantly in a wide range of tumours of different tissue origin. Human securin, hPTTG, takes part in the control of chromatid separation, and its anomalous expression promotes a deregulated segregation of chromosomes and the appearance of aneuploidies. The overexpression of PTTG1 could have relevance as a tumour marker as it is associated with tumours exhibiting a high degree of malignancy and the appearance of metastasis. We study the relationship between the overexpression of PTTG1 and chromosomal instability and its role in pre-invasive cancerous lesions. We also examine the role of PTTG1 securin in the modulation of tumour cell sensitivity to chemotherapeutic agents which affect the stability of microtubules. Finally, we study the capacity for tumour cell invasion in relation to PTTG1 expression levels and the expression of proteins related to invasion and metastasis, which are induced by PTTG1. These lines of work are undertaken in collaboration with groups from the University of Seville and CSIC.
Mechanisms of blocking apoptosis pathways responsible for progression and hormone resistance in hormone-dependent cancer.
Prostate cancer is one of the world's main causes of death by cancer. A high proportion of prostate cancers are diagnosed in advanced stages, in which androgenic deprivation is a palliative treatment that improves survival outcomes. Most patients evolve to a state of hormone independence, although the mechanisms underlying this phenomenon remain unclear. Defects in apoptosis signalling pathways are frequent in tumour cells and the imbalance these alterations produce to thereby increase cell survival plays an important role in both tumour progression and in the response to chemotherapy. Proteins of the Bcl-2 family play a critical role in the activation of the mitochondrial apoptotic route. Neoplastic cells develop specific mechanisms to avoid apoptosis which are involved in tumour progression and the development of resistance to different therapeutic agents. Our working hypothesis is based on the possible mechanisms that block the pro-apoptotic proteins Bax and Bak, in which anti-apoptotic members of the Bcl-2 family take part, especially Bcl-xL, as well as other proteins such as Ku70 and PTTG1. We study the presence of these interactions in non-stimulated cells as well as in cells treated with different stimuli to determine the possible involvement of these interactions in the resistance to apoptosis.
Solans-Laque, R; Rodriguez-Carballeira, M; Rios-Blanco, JJ; Fraile, G; Saez-Comet, L; Martinez-Zapico, A; Frutos, B; Solanich, X; Fonseca-Aizpuru, E; Pasquau-Liano, F; Zamora, M; Oristrell, J; Fanlo, P; Lopez-Dupla, M; Abdilla, M; Garcia-Sanchez, I; Sopena, B; Castillo, MJ; Perales, I; Callejas, JL
Comparison of the Birmingham Vasculitis Activity Score and the Five-Factor Score to Assess Survival in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Study of 550 Patients From Spain (REVAS Registry)
ARTHRITIS CARE & RESEARCH
Rubio-Rivas, M; Corbella, X; Guillen-del-Castillo, A; Vilella, CT; Arguelles, DC; Argibay, A; Hitos, JAV; Parra, JAT; Gonzalez-Echavarri, C; Ortego-Centeno, N; Martinez, LT; Carballeira, MR; Ballve, AM; Salas, XP; Fraile, IP; Chamorro, AJ; Vuelta, ABM; Freire, M; Munoz, MR; Garcia, AG; del Campo, IPM; Garcia, MES; Bello, DB; Espinosa, G; Hernandez, FJG; Comet, LS; Blanco, JJR; Gimenez, RAFD; Trigo, SS; Pla, VF; Aznar, CPS
Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: Derivation and internal validation
AUTOIMMUNITY REVIEWS
Gasca, J; Flores, ML; Jimenez-Guerrero, R; Saez, ME; Barragan, I; Ruiz-Borrego, M; Tortolero, M; Romero, F; Saez, C; Japon, MA
EDIL3 promotes epithelial-mesenchymal transition and paclitaxel resistance through its interaction with integrin alpha(V)beta(3)in cancer cells
CELL DEATH DISCOVERY
Galindo-Moreno, M; Giraldez, S; Limon-Mortes, MC; Belmonte-Fernandez, A; Saez, C; Japon, MA; Tortolero, M; Romero, F
p53 and FBXW7: Sometimes Two Guardians Are Worse than One
CANCERS
Flores-Martinez, A; Venegas-Moreno, E; Dios, E; Remon-Ruiz, P; Gros-Herguido, N; Vazquez-Borrego, MC; Madrazo-Atutxa, A; Japon, MA; Kaen, A; Cardenas-Valdepenas, E; Roldan, F; Castano, JP; Luque, RM; Cano, DA; Soto-Moreno, A
Quantitative Analysis of Somatostatin and Dopamine Receptors Gene Expression Levels in Non-functioning Pituitary Tumors and Association with Clinical and Molecular Aggressiveness Features
JOURNAL OF CLINICAL MEDICINE
Felipe-Abrio B, Verdugo-Sivianes EM, Sáez C, Carnero A ..
Loss of MYBBP1A Induces Cancer Stem Cell Activity in Renal Cancer.
Cancers (Basel)
Galindo-Moreno M, Giráldez S, Limón-Mortés MC, Belmonte-Fernández A, Reed SI, Sáez C, Japón MÁ, Tortolero M, Romero F
SCF(FBXW7)-mediated degradation of p53 promotes cell recovery after UV-induced DNA damage.
FASEB J.
Mavillard F, Madruga-Garrido M, Rivas E, Servián-Morilla E, Ávila-Polo R, Marcos I, Morón FJ, Paradas C, Cabrera-Serrano M
NOVEL intronic CAPN3 Roma mutation alters splicing causing RNA mediated decay.
Ann Clin Transl Neurol.
Venegas-Moreno E, Flores-Martinez A, Dios E, Vazquez-Borrego MC, Ibañez-Costa A, Madrazo-Atutxa A, Japón MA, Castaño JP, Luque RM, Cano DA, Soto-Moreno A
E-cadherin expression is associated with somatostatin analogue response in acromegaly.
J Cell Mol Med.
Escudero-Ávila R, Rodríguez-Castaño JD, Osman I, Fernandez F, Medina R, Vargas B, Japón-Rodríguez M, Sancho P, Perez-Valderrama B, Praena-Fernández JM, Duran I
Active surveillance as a successful management strategy for patients with clinical stage I germ cell testicular cancer.
Clin Transl Oncol.
Ávila-Polo R, Malfatti E, Lornage X, Cheraud C, Nelson I, Nectoux J, Böhm J, Schneider R, Hedberg-Oldfors C, Eymard B, Monges S, Lubieniecki F, Brochier G, Thao Bui M, Madelaine A, Labasse C, Beuvin M, Lacène E, Boland A, Deleuze JF, Thompson J, Richard I, Taratuto AL, Udd B, Leturcq F, Bonne G, Oldfors A, Laporte J, Romero NB.
Loss of Sarcomeric Scaffolding as a Common Baseline Histopathologic Lesion in Titin-Related Myopathies.
J Neuropathol Exp Neurol.
González-Molina W, Ávila-Polo R, Morales-Camacho RM, Vargas MT, Bernal R, Prats-Martín C.
Bone marrow erythrocyte and neutrophil phagocytosis and cannibalism by neuroendocrine carcinoma.
Br J Haematol.
Jiménez-Guerrero R, Gasca J, Flores ML, Pérez-Valderrama B, Tejera-Parrado C, Medina R, Tortolero M, Romero F, Japón MA, Sáez C.
Obatoclax and Paclitaxel Synergistically Induced Apoptosis and Overcome Paclitaxel Resistance in Urothelial Cancer Cells.
Cancers (Basel).
Luz Flores M, Sáez C.
Protocols for the Study of Taxanes Chemosensitivity in Prostate Cancer.
Methods Mol Biol.
Ramos-Campoy O, Ávila-Polo R, Grau-Rivera O, Antonell A, Clarimón J, Rojas-García R, Charif S, Santiago-Valera V, Hernández I, Aguilar M, Almenar C, López-Villegas D, Bajo L, Pastor P, Van der Zee J, Lladó A, Sánchez-Valle R, Gelpi E.
Systematic Screening of Ubiquitin/p62 Aggregates in Cerebellar Cortex Expands the Neuropathological Phenotype of the C9orf72 Expansion Mutation.
J Neuropathol Exp Neurol.
Venegas-Moreno E, Vazquez-Borrego MC, Dios E, Gros-Herguido N, Flores-Martinez A, Rivero-Cortés E, Madrazo-Atutxa A, Japón MA, Luque RM, Castaño JP, Cano DA, Soto-Moreno A.
Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly.
J Cell Mol Med.
. Vicente-Pascual M, Rossi M, Gámez J, Lladó A, Valls J, Grau-Rivera O, Ávila Polo R, Llorens F, Zerr I, Ferrer I, Nos C, Parchi P, Sánchez-Valle R, Gelpí E.
Variably protease-sensitive prionopathy presenting within ALS/FTD spectrum
Ann Clin Transl Neurol.
Cassinello J, Arranz JÁ, Piulats JM, Sánchez A, Pérez-Valderrama B, Mellado B, Climent MÁ, Olmos D, Carles J, Lázaro M.
SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017).
Clin Transl Oncol.
Vazquez-Borrego, MC; Gupta, V; Ibanez-Costa, A; Gahete, MD; Venegas-Moreno, E; Toledano-Delgado, A; Cano, DA; Blanco-Acevedo, C; Ortega-Salas, R; Japon, MA; Barrera-Martin, A; Vasiljevic, A; Hill, J; Zhang, SW; Halem, H; Solivera, J; Raverot, G; Galvez, MA; Soto-Moreno, A; Paez-Pereda, M; Culler, MD; Castano, JP; Luque, RM
A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
CLINICAL CANCER RESEARCH
